Ovarian cancer is a common cancer for females, and the incidence and mortality rates are on the rise. Many treatment strategies have been developed for ovarian cancer, including chemotherapy and immunotherapy, but they are often ineffective and prone to drug resistance. Protein ubiquitination is an important class of post-translation modifications that have been found to be associated with various human diseases and cancer development. Recent studies have revealed that protein ubiquitination is involved in the progression of ovarian cancer and plays an important role in the tumor immune process. Moreover, the combination of ubiquitinase/deubiquitinase inhibitors and cancer immunotherapy approaches can effectively reduce treatment resistance and improve treatment efficacy, which provides new ideas for cancer treatment. Herein, we review the role of protein ubiquitination in relation to ovarian cancer immunotherapy and recent advances in the use of ubiquitinase/deubiquitinase inhibitors in combination with cancer immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382211 | PMC |
| http://dx.doi.org/10.1016/j.gendis.2023.101158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population.
Breast Cancer Res
January 2025
Servicio de Oncología, Centro Universitario Contra el Cáncer (CUCC), Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, 66451, Monterrey, Nuevo León, México.
Background: Hereditary predisposition to breast and ovarian cancer syndrome (HBOC) is a pathological condition with increased cancer risk, including breast (BC), ovarian cancer (OC), and others. HBOC pathogenesis is caused mainly by germline pathogenic variants (GPV) in BRCA1 and BRCA2 genes. However, other relevant genes are related to this syndrome diagnosis, prognosis, and treatment, including TP53, PALB2, CHEK2, ATM, etc.
View Article and Find Full Text PDFDiagnostic accuracy of artificial intelligence algorithms to predict remove all macroscopic disease and survival rate after complete surgical cytoreduction in patients with ovarian cancer: a systematic review and meta-analysis.
BMC Surg
January 2025
Department of Obstetrics and Gynecology, Firoozgar Clinical Research and Development Center (FCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Background: Complete Cytoreduction (CC) in ovarian cancer (OC) has been associated with better outcomes. Outcomes after CC have a multifactorial and interrelated cause that may not be predictable by conventional statistical methods. Artificial intelligence (AI) may be more accurate in predicting outcomes.
View Article and Find Full Text PDFMolecular subtype of ovarian clear cell carcinoma: an analysis of 80 Chinese patients using the TCGA molecular classification of endometrial cancer.
BMC Cancer
January 2025
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.
Background: To assess the utility of the TCGA molecular classification of endometrial cancer in a well-annotated, moderately sized, consecutive cohort of Chinese patients with ovarian clear cell carcinoma (OCCC).
Methods: We performed DNA sequencing on 80 OCCC patients via a panel that contains 520 cancer-related genes. The TCGA molecular subtyping method was utilized for classification.
Clinical characteristics and laparoscopic management experience of primary ovarian leiomyoma.
Sci Rep
January 2025
Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Primary leiomyoma is one of the rarest benign ovarian tumors. Since the first case was identified, less than 100 cases have been reported worldwide. This study aimed to analyze the clinical characteristics and discuss the proper management of this tumor.
View Article and Find Full Text PDFA Multimodal Model Based on Transvaginal Ultrasound-Based Radiomics to Predict the Risk of Peritoneal Metastasis in Ovarian Cancer: A Multicenter Study.
Acad Radiol
January 2025
Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China (Y.Z., Y.D., Q.Z., C.Z.). Electronic address:
Rationale And Objectives: This study aimed to develop a predictive model for peritoneal metastasis (PM) in ovarian cancer using a combination radiomics and clinical biomarkers to improve diagnostic accuracy.
Patients And Methods: This retrospective cohort study of 619 ovarian cancer patients involved demographic data, radiomics, O-RADS standardized description, clinical biomarkers, and histological findings. Radiomics features were extracted using 3D Slicer and Pyradiomics, with selective feature extraction using Least Absolute Shrinkage and Selection Operator regression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!